|
1.
|
|
12 p, 2.6 MB |
Concordance of p16INK4a and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study
/
Mena, Marisa (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública. Instituto de Salud Carlos III) ;
Wang, Xin (Institut d'Investigació Biomèdica de Bellvitge) ;
Tous, Sara (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública. Instituto de Salud Carlos III) ;
Quirós, Beatriz (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública. Instituto de Salud Carlos III) ;
Clavero, Omar (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública. Instituto de Salud Carlos III) ;
Alejo, Maria (Hospital General de l'Hopitalet. Pathology Department) ;
Morey, Francisca (Institut d'Investigació Biomèdica de Bellvitge) ;
Taberna, Miren (Institut d'Investigació Biomèdica de Bellvitge) ;
León i Vintró, Xavier (Institut d'Investigació Biomèdica Sant Pau) ;
Lloveras Rubio, Belén (Hospital del Mar. Pathology Department) ;
Alos, Llucìa (Hospital Clínic i Provincial de Barcelona) ;
Mehanna, Hisham (Institute of Head and Neck Studies and Education. University of Birmingham) ;
Quint, Wim (DDL Diagnostic Laboratory) ;
Pawlita, Michael (Division of Molecular Diagnostics of Oncogenic Infections. Research Program Infection. Inflammation and Cancer. German Cancer Research Center (DKFZ)) ;
Tommasino, Massimo (Infections and Cancer Biology Group. International Agency for Research on Cancer (IARC)) ;
Pavón, Miguel Angel (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública. Instituto de Salud Carlos III) ;
Muñoz, Nubia (National Cancer Institute) ;
De Sanjose, Silvia (ISGlobal) ;
Bosch, Francesc Xavier (Universitat Oberta de Catalunya) ;
Alemany, Laia (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública. Instituto de Salud Carlos III)
Background: Tests or test algorithms for diagnosing HPV-driven oral cavity and laryngeal head and neck carcinomas (HNC) have not been yet validated, and the differences among oral cavity and laryngeal sites have not been comprehensively evaluated. [...]
2022 -  10.3390/cancers14153787
Cancers, Vol. 14 Núm. 15 (august 2022) , p. 3787
|
|
|
2.
|
|
13 p, 2.5 MB |
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
/
Ribeiro, Marcelo Lima (Sao Francisco University Medical School. Laboratory of Immunopharmacology and Molecular Biology) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blecua, Pedro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Reyes Garau, Diana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Armengol, Marc Antoni (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Serrano, Miranda (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Miskin, Hari P. (TG Therapeutics (New York)) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Esteller, M. (Institució Catalana de Recerca i Estudis Avançats) ;
Normant, Emmanuel (TG Therapeutics (New York)) ;
Roué, Gaël (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody that targets CD47 selectively on CD19+ B-cells, is under clinical evaluation in relapsed/refractory (R/R) B-NHL patients either as a single-agent or in combination with ublituximab, a new generation CD20 antibody. [...]
2023 - 10.3389/fimmu.2023.1130052
Frontiers in immunology, Vol. 14 (April 2023) , art. 1130052
|
|
|
3.
|
|
11 p, 1.4 MB |
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma
/
Ribeiro, Marcelo Lima (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Reyes, Diana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Armengol, Marc Antoni (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Serrano, Miranda (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sedó Mor, Alícia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bech-Serra, Joan-Josep (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blecua, Pedro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Musulén, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
De La Torre Gómez, Gisela Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Miskin, Hari (TG Therapeutics (Nova York)) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Normant, Emmanuel (TG Therapeutics (Nova York)) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Despite the remarkable activity of BTK inhibitors (BTKi) in relapsed B-cell non-Hodgkin lymphoma (B-NHL), no clinically-relevant biomarker has been associated to these agents so far. The relevance of phosphoproteomic profiling for the early identification of BTKi responders remains underexplored. [...]
2021 - 10.1158/1078-0432.CCR-21-1067
Clinical Cancer Research, Vol. 27 (september 2021) , p. 6591-6601
|
|
|
4.
|
|
1 p, 80.2 KB |
Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
/
Dlouhy, Ivan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Armengol, Marc Antoni (Universitat Autònoma de Barcelona) ;
Recasens-Zorzo, Clara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ribeiro, Marcelo L. (Universidade São Francisco) ;
Pérez-Galán, Patricia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
López Guillermo, Armando (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
2022 - 10.3324/haematol.2022.281988
Haematologica, Vol. 107 (december 2022) , p. 2990
|
|
|
5.
|
|
14 p, 1.3 MB |
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)
/
Gordon, Leo I. (Northwestern University Feinberg School of Medicine) ;
Karmali, Reem (Northwestern University Feinberg School of Medicine) ;
Kaplan, Jason B. (Northwestern University Feinberg School of Medicine) ;
Popat, Rakesh (University College London) ;
Burris, Howard A. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Ferrari, Silvia (Ospedale Papa Giovanni XXIII) ;
Madan, Sumit (Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA) ;
Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ;
Gritti, Giuseppe (Ospedale Papa Giovanni XXIII) ;
El-Sharkawi, Dima (Royal Marsden Hospital (Regne Unit)) ;
Chau, F. Ian (Royal Marsden Hospital (Regne Unit)) ;
Radford, John (University of Manchester) ;
de Oteyza, Jaime Pérez (Hospital Universitario HM Sanchinarro (Madrid)) ;
Zinzani, Pier Luigi (Università di Bologna) ;
Iyer, Swaminathan P. (University of Texas MD Anderson Cancer Center) ;
Townsend, William (University College London Hospitals) ;
Miao, Harry (Takeda Development Center Americas) ;
Proscurshim, Igor (Takeda Development Center Americas) ;
Wang, Shining (Takeda Development Center Americas) ;
Katyayan, Shilpi (Labcorp Drug Development (Estats Units d'Amèrica)) ;
Yuan, Ying (Takeda Development Center Americas) ;
Zhu, Jiaxi (Takeda Development Center Americas) ;
Stumpo, Kate (Takeda Development Center Americas) ;
Shou, Yaping (Takeda Development Center Americas) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona)
We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). [...]
2023 - 10.18632/oncotarget.28352
Oncotarget, Vol. 14 (january 2023) , p. 57-70
|
|
|
6.
|
|
1 p, 825.9 KB |
Correction : Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
/
Mansouri, Larry (Karolinska Institutet (Estocolm, Suècia)) ;
Thorvaldsdottir, Birna (Karolinska Institutet (Estocolm, Suècia). Department of Molecular Medicine and Surgery) ;
Sutton, Lesley-Ann (Karolinska Institutet (Estocolm, Suècia)) ;
Karakatsoulis, Georgios (University of Ioannina) ;
Meggendorfer, Manja (MLL Munich Leukemia Laboratory) ;
Parker, Helen (University of Southampton) ;
Nadeu, Ferran (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Brieghel, Christian (Copenhagen University Hospital) ;
Laidou, Stamatia (Institute of Applied Biosciences) ;
Moia, Riccardo (Università del Piemonte Orientale) ;
Rossi, Davide (Institute of Oncology Research) ;
Catherwood, Mark (Queen's University Belfast) ;
Kotaskova, Jana (Masaryk University) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez-Vicente, Ana E. (Universidad de Salamanca) ;
Benito, Rocío (Universidad de Salamanca) ;
Rigolin, Gian Matteo (University of Ferrara) ;
Bonfiglio, Silvia (Università Vita Salute San Raffaele) ;
Scarfo, Lydia (Università Vita Salute San Raffaele) ;
Mattsson, Mattias (Uppsala University) ;
Davis, Zadie (University Hospitals Dorset) ;
Gogia, Ajay (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Rani, Lata (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Baliakas, Panagiotis (Uppsala University) ;
Foroughi-Asl, Hassan (Karolinska Institutet (Estocolm, Suècia)) ;
Jylhä, Cecilia (Karolinska Institutet (Estocolm, Suècia)) ;
Skaftason, Aron (Karolinska Institutet (Estocolm, Suècia)) ;
Rapado, Inmaculada (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Miras, Fatima (Hospital Universitario 12 de Octubre (Madrid)) ;
Martinez-Lopez, Joaquín (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
de la Serna, Javier (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Rivas, Jesús María Hernández (Universidad de Salamanca) ;
Thornton, Patrick (Beaumont Hospital (Dublín, Irlanda)) ;
Larráyoz, María José (Universidad de Navarra) ;
Calasanz, M.J (Universidad de Navarra) ;
Fésüs, Viktória (Semmelweis University) ;
Mátrai, Zoltán (Central Hospital of Southern Pest-National Institute of Hematology and Infectious Diseases (Budapest, Hongria)) ;
Bödör, Csaba (Semmelweis University) ;
Smedby, Karin E. (Karolinska Institutet (Estocolm, Suècia)) ;
Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gupta, Ritu (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Bullinger, Lars (Charité - Universitätsmedizin Berlin) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Tazón-Vega, Bárbara (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Baran-Marszak, Fanny (Hôpital Avicenne AP-HP) ;
Oscier, David (University Hospitals Dorset) ;
Nguyen-Khac, Florence (Sorbonne University) ;
Zenz, Thorsten (University Hospital of Zurich) ;
Terol, Maria Jose (Universitat de València) ;
Cuneo, Antonio (University of Ferrara) ;
Hernández-Sánchez, María (Universidad de Salamanca) ;
Pospisilova, Sarka (Masaryk University) ;
Mills, Ken (Queen's University Belfast) ;
Gaidano, Gianluca (Università del Piemonte Orientale) ;
Niemann, Carsten U. (Copenhagen University Hospital) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
Strefford, Jonathan C. (University of Southampton) ;
Ghia, Paolo (Università Vita Salute San Raffaele) ;
Stamatopoulos, Kostas (Institute of Applied Biosciences) ;
Rosenquist, Richard (Karolinska University Hospital and Karolinska Institutet (Suècia))
2023 - 10.1038/s41375-023-01813-3
Leukemia, Vol. 37 (january 2023) , p. 504
|
|
|
7.
|
|
9 p, 1.7 MB |
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status : a study by ERIC in HARMONY
/
Mansouri, Larry (Karolinska Institutet (Estocolm, Suècia)) ;
Thorvaldsdottir, Birna (Karolinska Institutet (Estocolm, Suècia)) ;
Sutton, Lesley-Ann (Karolinska Institutet (Estocolm, Suècia)) ;
Karakatsoulis, Georgios (University of Ioannina. Department of Mathematics) ;
Meggendorfer, Manja (MLL Munich Leukemia Laboratory) ;
Parker, Helen (University of Southampton) ;
Nadeu, Ferran (Centro de Investigación Biomédica en Red de Cáncer) ;
Brieghel, Christian (Copenhagen University Hospital. Department of Hematology, Rigshospitalet) ;
Laidou, Stamatia (Centre for Research and Technology Hellas (Tessalònica, Grècia)) ;
Moia, Riccardo (Università del Piemonte Orientale) ;
Rossi, Davide (Institute of Oncology Research (Suïssa)) ;
Catherwood, Mark (Queen's University Belfast) ;
Kotaskova, Jana (Masaryk University) ;
Delgado, Julio (Universitat de Barcelona) ;
Rodríguez-Vicente, Ana E. (Hospital Universitario de Salamanca) ;
Benito, Rocío (Hospital Universitario de Salamanca) ;
Rigolin, Gian Matteo (University of Ferrara) ;
Bonfiglio, Silvia (Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Scarfo, Lydia (Università Vita Salute San Raffaele) ;
Mattsson, Mattias (Uppsala University. Department of Immunology, Genetics and Pathology) ;
Davis, Zadie (Molecular Pathology Department, University Hospitals Dorset) ;
Gogia, Ajay (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Rani, Lata (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Baliakas, Panagiotis (Uppsala University. Department of Immunology, Genetics and Pathology) ;
Foroughi-Asl, Hassan (Karolinska Institutet (Estocolm, Suècia)) ;
Jylhä, Cecilia (Karolinska Institutet (Estocolm, Suècia)) ;
Skaftason, Aron (Karolinska Institutet (Estocolm, Suècia)) ;
Rapado, Inmaculada (Spanish National Cancer Research) ;
Miras, Fatima (Hospital Universitario 12 de Octubre (Madrid)) ;
Martinez-Lopez, Joaquín (Spanish National Cancer Research) ;
de la Serna, Javier (Spanish National Cancer Research) ;
Rivas, Jesús María Hernández (Hospital Universitario de Salamanca) ;
Thornton, Patrick (Beaumont Hospital. Haematology Department) ;
Larráyoz, María José (Instituto de Investigación Sanitaria de Navarra) ;
Calasanz, M.J (Instituto de Investigación Sanitaria de Navarra) ;
Fésüs, Viktória (Semmelweis University) ;
Mátrai, Zoltán (Central Hospital of Southern Pest-National Institute of Hematology and Infectious Diseases, Budapest, Hungary) ;
Bödör, Csaba (Semmelweis University) ;
Smedby, Karin E. (Karolinska Institutet (Suècia). Department of Medicine Solna) ;
Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gupta, Ritu (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Bullinger, Lars (Charité - Universitätsmedizin Berlin) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Tazón-Vega, Bárbara (Vall d'Hebron Institut d'Oncologia) ;
Baran-Marszak, Fanny (Service d'hématologie Biologique Hôpital Avicenne Assistance Publique des Hôpitaux de Paris) ;
Oscier, David (University Hospitals Dorset) ;
Nguyen-Khac, Florence (Sorbonne University) ;
Zenz, Thorsten (University Hospital and University of Zurich. Department of Oncology and Haematology) ;
Terol, Maria Jose (University of Valencia. Department of Hematology) ;
Cuneo, Antonio (University of Ferrara. Hematology-Department of Medical Sciences) ;
Hernández-Sánchez, María (Hospital Universitario de Salamanca) ;
Pospisilova, Sarka (Masaryk University. Central European Institute of Technology) ;
Mills, Ken (Queen's University Belfast) ;
Gaidano, Gianluca (Università del Piemonte Orientale) ;
Niemann, Carsten U. (Copenhagen University Hospital) ;
Campo, Elias (Universitat de Barcelona) ;
Strefford, Jonathan C. (University of Southampton) ;
Ghia, Paolo (Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Stamatopoulos, Kostas (Institute of Applied Biosciences (Grècia)) ;
Rosenquist, Richard (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Universitat Autònoma de Barcelona
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. [...]
2022 - 10.1038/s41375-022-01802-y
Leukemia, Vol. 37 (december 2022) , p. 339-347
|
|
|
8.
|
|
11 p, 865.1 KB |
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
/
Abrisqueta, Pau (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Medina, Daniel (Vall d'Hebron Institut d'Oncologia) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Lu, Junyan (European Molecular Biology Laboratory (Alemanya)) ;
Alcoceba, Miguel (Centro de Investigación Biomédica en Red de Cáncer) ;
Carabia, Júlia (Vall d'Hebron Institut d'Oncologia) ;
Boix, Joan (Vall d'Hebron Institut d'Oncologia) ;
Tazón-Vega, Barbara (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Bobillo, Sabela (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Marín-Niebla, Ana (Universitat Autònoma de Barcelona. Departament de Medicina) ;
González, Marcos (Centro de Investigación Biomédica en Red de Cáncer) ;
Zenz, Thorsten (University of Zurich. Department of Medical Oncology and Hematology) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona. Departament de Medicina)
Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. [...]
2022 - 10.1182/bloodadvances.2022007508
Blood advances, Vol. 6 (august 2022) , p. 5763-5773
|
|
|
9.
|
|
34 p, 298.5 KB |
La clasificación de los empleados públicos tras la ley 20/2021 de reducción del empleo público y el RD-ley 32/2021 de reforma del mercado de trabajo
/
Boltaina Bosch, Xavier (Universitat Oberta de Catalunya)
El presente documento analiza el régimen jurídico esencial que conforma las dos modalidades de empleo público temporal en la Administración Pública tras la Ley 20/2021 de reducción de la temporalidad y el RD-ley 32/2021 de reforma laboral, en cuanto al personal funcionario interino y el personal laboral temporal. [...]
El present document analitza el règim jurídic essencial que conforma les dues modalitats d'ocupació pública temporal en l'Administració Pública després de la Llei 20/2021 de reducció de la temporalitat i el RD-llei 32/2021 de reforma laboral, quant al personal funcionari interí i el personal laboral temporal. [...]
This document analyses the essential legal regime that shapes the two types of temporary public employment in the Public Administration after Law 20/2021 on the reduction of temporary employment and RD-Law 32/2021 on labour reform, in terms of interim civil servant staff and temporary labour staff. [...]
2022 - 10.5565/rev/aiet.107
Anuario IET de trabajo y relaciones laborales, Vol. 8 (2022) , p. 65-98 (Anàlisi des de la perspectiva del Dret Laboral)
|
|
|
10.
|
|
10 p, 2.2 MB |
ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation
/
Calpe, Eva (Hospital Universitari Vall d'Hebron) ;
Purroy i Zuriguel, Noèlia (Hospital Universitari Vall d'Hebron) ;
Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Carabia, Júlia (Hospital Universitari Vall d'Hebron) ;
Palacio-García, Carles (Hospital Universitari Vall d'Hebron) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
ZAP-70 in chronic lymphocytic leukemia (CLL) is associated with enhanced response to microenvironmental stimuli. We analyzed the functional consequences of ZAP-70 ectopic expression in malignant B-cells in a xenograft mouse model of disseminated B-cell leukemia. [...]
2013 - 10.1371/journal.pone.0081221
PloS one, Vol. 8 (december 2013)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
